Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough

Thursday, May 11th, 2023

This Phase 2a, randomized, double-blind, crossover study examined the efficacy and safety of sivopixant versus placebo in 31 patients with refractory or unexplained chronic cough. The primary endpoint was the placebo-adjusted ratio of day time average hourly cough count at 2 weeks versus baseline; secondary endpoints included the ratio of 24-hour, night-time, awake, and asleep average hourly cough counts at 2 weeks versus baseline, change in Leicester Cough Questionnaire score, change in cough severity, and change in EQ-5D-5L and EQ-VAS scores. During the study, cough counts were objectively measured using the Vitalograph VitaloJAK cough monitor.